Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions.
Latest Information Update: 20 Feb 2026
At a glance
- Drugs Antisense oligonucleotide EveryONE Medicines (Primary)
- Indications CNS disorders
- Focus Adverse reactions
- Acronyms EOM-MP1
- Sponsors EveryONE Medicines
Most Recent Events
- 20 Feb 2026 New trial record